Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
818.93
-10.81 (-1.30%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
September 24, 2024
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?
Via
MarketBeat
Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market
September 24, 2024
Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive impairment and dementia stages. The approval is based on data showing Kisunla...
Via
Benzinga
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity
September 23, 2024
Via
Benzinga
Investing in This Healthcare Stock Could Be Like Catching Nvidia at the Dawn of the AI Boom
September 22, 2024
Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business following a similar trajectory.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
September 21, 2024
History shows that Eli Lilly tends to do something special with its stock toward the end of the year.
Via
The Motley Fool
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
September 21, 2024
NFLX is among four stocks on the list that's actionable now.
Via
Investor's Business Daily
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
September 20, 2024
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Via
The Motley Fool
In-Depth Analysis: Eli Lilly Versus Competitors In Pharmaceuticals Industry
September 20, 2024
Via
Benzinga
Looking Into Eli Lilly's Recent Short Interest
September 17, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly
September 17, 2024
Via
Benzinga
6 Incredible Reasons to Invest in Eli Lilly
September 13, 2024
The drug giant's winning ways look set to continue for a while.
Via
The Motley Fool
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
September 20, 2024
FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules
September 20, 2024
Eli Lilly appeals a $183 million judgment in a Medicaid fraud case, arguing that it followed a reasonable interpretation of the law. The case has drawn attention from major business and pharmaceutical...
Via
Benzinga
Topics
Fraud
Exposures
Legal
Why Tandem Diabetes Care Stock Thrashed the Market Today
September 19, 2024
At a stroke, it's got a product authorized for a specific use in 27 countries.
Via
The Motley Fool
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.
Via
Investor's Business Daily
Looking At Eli Lilly's Recent Unusual Options Activity
September 12, 2024
Via
Benzinga
1 Unstoppable Stock That Could Join the $1 Trillion Club in 2025
September 19, 2024
Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.
Via
The Motley Fool
Prediction: This Will be Eli Lilly's Next Big Move.
September 19, 2024
Lilly could take a step that's positive for the stock and investors over the long term.
Via
The Motley Fool
Why ResMed Stock Tumbled by 5% Today
September 18, 2024
A looming threat from a very powerful rival could significantly dampen a key business for the company.
Via
The Motley Fool
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
September 18, 2024
Terns has a modest market cap of less than $800 million, and its possible upside could be massive.
Via
The Motley Fool
ADX: A High-Yielding, Diversified CEF Worth Looking Into
September 18, 2024
When it comes to investing, there are two critical “bedrocks” we need to keep in mind. These two facts are why 95% of my favorite high-income investments, closed-end funds (CEFs), have made investors...
Via
Talk Markets
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club
September 17, 2024
Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the door of a trillion-dollar valuation.
Via
The Motley Fool
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
Telemedicine once seemed like it was going to revolutionize healthcare.
Via
The Motley Fool
Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss
September 16, 2024
The FDA has approved Eli Lilly's Ebglyss for moderate-to-severe eczema in patients 12 and older. The treatment is administered via monthly injections and demonstrated clear skin and itch relief in...
Via
Benzinga
Exposures
Product Safety
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
September 16, 2024
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr....
Via
Newsfile
3 Stocks to Buy and Hold Forever
September 14, 2024
These stocks are built for the long run.
Via
The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
September 13, 2024
The major indexes reclaimed key levels and many leaders flashed buy signals.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.